Improving early detection of liver cancer using advanced ultrasound techniques

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to enhance the early detection of hepatocellular carcinoma (HCC) by utilizing innovative quantitative ultrasound (QUS) techniques. The research will compare the effectiveness of conventional B-mode ultrasound with advanced QUS methods, including shear wave viscoelastography and sub-resolution cellular imaging, in identifying liver nodules. The study will involve adult patients undergoing routine ultrasound or MRI surveillance for liver cancer, with MRI serving as the reference standard for diagnosis. By improving detection rates, the study seeks to facilitate earlier treatment and improve survival outcomes for patients with liver cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Adult patients scheduled for US- or MRI-based surveillance of HCC or undergoing MRI-based imaging for characterization of liver nodules as part of their clinical standard of care.

Exclusion Criteria:

\- Patients with prior locoregional or systemic therapy.

Where it's running

• Centre Hospitalier de l'Université de Montréal (CHUM)
  Montreal, Quebec, Canada Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BGB-B2033 vs Sorafenib or Lenvatinib for advanced liver cancer

  This study tests whether the investigational drug BGB-B2033 can help people with advanced hepatocellular carcinoma when given after prior PD-1/PD-L1 therapy, compared with the standard medicines sorafenib or lenvatinib.

  Recruiting at 2 sites Phase 3 BeOne Medicines · South Brisbane, Queensland and 1 other locations · NCT07836530

• Tracking immune and genomic changes in liver cancer during immunotherapy

  This study will test whether blood and tumor biomarkers can predict how people with advanced hepatocellular carcinoma respond to immunotherapy.

  Recruiting Asan Medical Center · Seoul, Song-pa · NCT07186010

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Assessing blood biomarkers and MRI for liver cancer patients undergoing radiation therapy

  This study is testing if using special MRI scans and blood tests can help doctors keep track of liver health in patients with liver cancer who are getting radiation therapy.

  Recruiting Montefiore Medical Center · The Bronx, New York · NCT06899152

• Combining TACE and surgery for large liver tumors

  This study is testing if a treatment called TACE before surgery can help people with large liver tumors do better after surgery and have fewer chances of the cancer coming back.

  Recruiting Sun Yat-sen University · Beijing, Beijing Municipality · NCT06898398

• PSMA PET-guided Lu-177 radioligand therapy for metastatic hepatocellular carcinoma.

  This will test whether Lu-177 PSMA-617 can safely reach and shrink PSMA-positive metastatic hepatocellular carcinoma in adults whose cancer progressed after first-line treatment.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio · NCT06852820

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.